Immunovant
IMVT
115 hedge funds and large institutions have $1.37B invested in Immunovant in 2020 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 53 increasing their positions, 20 reducing their positions, and 11 closing their positions.
255% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 11
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
165% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 20
96% more capital invested
Capital invested by funds: $696M → $1.37B (+$670M)
32% more funds holding
Funds holding: 87 → 115 (+28)
2% more ownership
Funds ownership: 43.23% → 45.23% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$53.9M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$49.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$44.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$41M |
| 5 |
BlackRock
New York
|
+$36.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$31.9M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$15.2M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$14.4M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$10.9M |
| 5 |
O
OrbiMed
New York
|
-$8.63M |
IMVT Hedge Fund Activity: Q3 2020 in Review
115 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q3 2020, worth a combined $1.37B — up 96% from $696M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new IMVT positions and 11 closed out — a net gain of 28 holders — while 53 added to existing stakes and 20 trimmed.
The largest buyer was RTW Investments, adding an estimated $53.9M. The largest seller was Adage Capital Partners, cutting an estimated $31.9M.
- 115 institutional investors held Immunovant (IMVT) as of Q3 2020, up from 87 in Q2 2020.
- Funds reported $1.37B of Immunovant stock for Q3 2020, up 96% quarter-over-quarter.
- 39 funds opened new Immunovant positions in Q3 2020 and 11 closed out, a net change of +28 holders.
- The largest Immunovant buyer in Q3 2020 was RTW Investments, an estimated $53.9M added.
- The largest Immunovant seller in Q3 2020 was Adage Capital Partners, an estimated $31.9M sold.
Based on aggregated 13F filings for Q3 2020.